ABSTRACT
Introduction There is an absence of real-world evidence, especially from low- and middle-income countries (LMICs), on the implementation successes and challenges of COVID-19 test and treat (T&T) programs. In 2022, nirmatrelvir/ritonavir was provided as standard of care for mild to moderate COVID-19 treatment in eight LMICs (Ghana, Kenya, Laos, Malawi, Nigeria, Rwanda, Uganda and Zambia). This manuscript describes a research protocol to study novel drug introduction during the COVID-19 health emergency, with implications and learnings for future pandemic preparedness. The goal of the study is to provide simultaneous program learnings and improvements with program rollout, to fill a gap in real-world implementation data on T&T programs of oral antiviral treatment for COVID-19 and inform program implementation and scale-up in other LMICs.
Methods and analysis This multiple methods implementation research study is divided into three components to address key operational research objectives: 1) program learnings, monitoring and evaluation; 2) patient-level program impact; and 3) key stakeholder perspectives. Data collection will occur for a minimum of six months in each country, up to the end of grant. Quantitative data will be analysed using descriptive statistics for each country and then aggregated across the program countries. Stakeholder perspectives will be examined using the Consolidated Framework for Implementation Research implementation science framework and semi-structured interviews.
Ethics and dissemination This study was approved by the Duke University Institutional Review Board (Pro00111388), The study was also approved by the local institutional review boards in each country participating in individual-level data collection (Objectives 2 and 3): Ghana, Malawi, Rwanda and Nigeria. The study’s findings will be published in peer-reviewed journals and disseminated through dialogue events, national and international conferences and through social media.
Trial registration number Clinicaltrials.gov NCT06360783.
STRENGTHS AND LIMITATIONS OF THIS STUDY
The knowledge generated though this study will improve understanding of the key characteristics of a strong test and treat (T&T) program, and may translate to improved local T&T program implementation and better patient outcomes.
This study uses real-world routinely collected health data and is not designed as a randomised trial; therefore, data quality may be a challenge and the study cannot be used to compare patient outcomes.
This study protocol could be adapted to rapidly assess rollout of test and treat interventions to provide real-time learnings in health emergencies.
Lessons learned from this study could be applied to other T&T scenarios, particularly around new product introduction, and provide reciprocal innovations to other countries and contexts on the feasibility, challenges, and successes of program implementation.
This study is designed to fill a gap in real-world implementation data on T&T programs of oral antiviral treatment for COVID-19 and inform program implementation and scale-up in low- and middle-income countries.
Competing Interest Statement
Implementing partners of the QuickStart study are the COVID Collaborative, Duke University, the Clinton Health Access Initiative, and Americares, with support from the Open Society Foundations, the Conrad N. Hilton Foundation, and Pfizer.
Funding Statement
This work was supported by Open Society Foundations, the Conrad N. Hilton Foundation, and Pfizer. The donors have no role in the design or analysis of this implementation research study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Duke University Institutional Review Board (Pro00111388), The study was also approved by the local institutional review boards in each country participating in individual-level data collection (Objectives 2 and 3): the Ghana Health Services Ethics Review Committee (017/11/22), the National Health Sciences Research Committee, Malawi (#23/03/4025), the Rwanda National Research Ethics Committee (105/RNEC/2023), the Institutional Review Board ERES Converge (Zambia) (23-Jan-023) and the National Health Research Ethics Committee in Nigeria (NHREC/01/01/2007-11/01/2024).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Denotes co-first authorship
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos